^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DFF332
i
Other names: DFF332, DFF 332, DFF-332
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis
Drug class:
HIF-2α inhibitor
Related drugs:
9ms
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2025 --> Feb 2025 | Trial primary completion date: Jul 2025 --> Feb 2025
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases • Immuno-oncology
|
VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
12ms
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov)
P1, N=40, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=180 --> 40
Enrollment closed • Enrollment change • Combination therapy • IO biomarker • Metastases • Immuno-oncology
|
VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
3years
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov)
P1, N=180, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy • IO biomarker
|
VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
3years
A Phase I/Ib study of DFF332 as a single agent and in combination with Everolimus or Immuno-oncology therapies in patients with advanced/relapsed ccRCC and other malignancies with HIF2alpha stabilizing mutations. (clinicaltrialsregister.eu)
P1, N=187, Ongoing, Novartis Pharma AG
Clinical • New P1 trial • Combination therapy
|
VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
over3years
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov)
P1, N=180, Not yet recruiting, Novartis Pharmaceuticals
Clinical • New P1 trial • Combination therapy • IO biomarker
|
VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • EPAS1 (Endothelial PAS domain protein 1) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2)
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
Share via
